The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians offer risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects. These recommendations ...
Sep 4, 2019
0
2
Tart cherry reduces the musculoskeletal effects of aromatase inhibitors in patients with non-metastatic breast cancer, according to new findings from a clinical trial by researchers at Marshall University Joan C. Edwards ...
Jun 10, 2019
0
0
The early-stage research, led by scientists from Imperial College London and The Institute of Cancer Research, London, identified a genetic 'switch' in breast cancer cells that boosts the production of a type of internal ...
May 30, 2019
0
351
The FRAX tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women ...
May 9, 2019
0
1
In 2017, the German Institute for Quality and Efficiency in Health Care (IQWiG) already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor versus the appropriate comparator ...
Apr 17, 2019
0
2
Vaginal dryness and painful intercourse are some of the more common adverse events of post-breast cancer treatment therapies and often lead to sexual dissatisfaction and an overall lower quality of life (QOL). However, a ...
Apr 17, 2019
0
0
(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...
Apr 6, 2019
0
3
Estrogen in the brain is important to keep neurons communicating and memories being made, scientists report.
Feb 25, 2019
0
652
Breast cancer will strike 1 in 8 women in her lifetime. But women who face an increased risk of being that one unlucky patient may improve their chances with three prescription medications, according to a new report.
Jan 18, 2019
0
11
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends risk-reducing medications for women at high risk for breast cancer who are at low risk for adverse events, but medications are not recommended for ...
Jan 16, 2019
0
0
